Zydus Lifesciences Limited (NSE:ZYDUSLIFE) filed a newspaper publication on 12 August 2026, disclosing an extract of its consolidated unaudited financial results for the quarter ended 30 June 2026, as published in the Financial Express on the same date, pursuant to SEBI Listing Regulations 30, 33, and 47.
Key Highlights
- Consolidated total income from operations for Q1 FY27 stood at INR 80,170 million, up from INR 65,737 million in Q1 FY26, representing year-on-year growth of approximately 22%.
- Net profit after tax and non-controlling interest for Q1 FY27 was INR 9,398 million, compared with INR 14,668 million in Q1 FY26 and INR 12,725 million in Q4 FY26.
- Basic and diluted earnings per share for Q1 FY27 were INR 9.35, against INR 14.58 in Q1 FY26 and INR 12.65 in Q4 FY26, on a non-annualised basis.
- Paid-up equity share capital as of 30 June 2026 stood at INR 998 million on a face value of Re. 1 per share, with other equity reported at INR 270,108 million for FY26.
About the Company
Zydus Lifesciences Limited (NSE:ZYDUSLIFE), headquartered in Ahmedabad and registered at Zydus Corporate Park, Sarkhej-Gandhinagar Highway, is a research-driven integrated global pharmaceutical company. The company develops and manufactures a broad range of pharmaceutical formulations, active pharmaceutical ingredients, biosimilars, and consumer wellness products, serving markets across India, the United States, Europe, and emerging economies. Its CIN is L24230GJ1995PLC025878.
Announcement in Detail
The filing, submitted by Company Secretary and Compliance Officer Dhaval N. Soni (FCS 7063), contains an extract of consolidated unaudited financial results for the quarter ended 30 June 2026, published in the Financial Express dated 12 August 2026. The submission is made under Regulation 30 read with Regulations 33 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The signing authority for the board is Managing Director Dr. Sharvil P. Patel (DIN: 00131995), and the document is dated 11 August 2026 from Ahmedabad.
On a quarter-on-quarter basis, total income from operations rose from INR 75,870 million in Q4 FY26 to INR 80,170 million in Q1 FY27. Net profit before exceptional items and tax declined from INR 20,572 million in Q4 FY26 to INR 13,248 million in Q1 FY27. Net profit after exceptional items but before tax was INR 13,066 million for Q1 FY27, against INR 16,597 million in Q4 FY26. Total comprehensive income after tax and non-controlling interest was INR 9,120 million in Q1 FY27.
Impact on Investors
Investors will note that while consolidated revenue showed year-on-year improvement, net profit after tax and non-controlling interest at INR 9,398 million for Q1 FY27 is materially lower than both the INR 14,668 million recorded in Q1 FY26 and the INR 12,725 million in Q4 FY26. The filing shows that exceptional items had a differential impact across periods, with net profit before exceptional items and tax declining quarter-on-quarter from INR 20,572 million to INR 13,248 million, a factor shareholders will observe when assessing the underlying operational trajectory.
The disclosed terms indicate that earnings per share on a non-annualised basis fell to INR 9.35 in Q1 FY27 from INR 14.58 in the corresponding quarter of the previous year. The full detailed results and Limited Review Reports are available on the BSE and NSE exchange portals, as noted in the filing, and investors are encouraged to refer to the complete document for a comprehensive assessment.
Sector / Market Context
India's pharmaceutical sector remains one of the country's largest export contributors, with the industry supplying over 200 countries according to the Pharmaceuticals Export Promotion Council of India. The US market, a critical revenue source for Indian generics companies, continues to see pricing pressures alongside opportunities from new product approvals. The Indian government's Production Linked Incentive scheme for pharmaceuticals, administered by the Department of Pharmaceuticals, has further shaped capacity investment decisions across the sector, influencing the operating environment in which integrated players such as Zydus Lifesciences operate.